Hemopurifier containing Galanthus nivalis resin removes SARS-CoV-2 variants Antiviral Coronavirus Disease COVID Efficacy SARSCoV2 PLOSONE
By Dr. Priyom Bose, Ph.D.Aug 2 2022Reviewed by Benedette Cuffari, M.Sc. To date, coronavirus disease 2019 , which is caused by infection with the severe acute respiratory syndrome coronavirus-2 , has infected over 575 million and claimed more than 6.4 million lives worldwide.
Background Several COVID-19 therapeutics and vaccines targeting the spike protein of the ancestral SARS-CoV-2 strain have been developed. Unfortunately, SARS-CoV-2 variants containing mutations in the spike region are associated with increased resistance to COVID-19 vaccination and therapeutics, such as monoclonal antibodies and antivirals.
One previous study reported that the Aethlon Hemopurifier device consisting of an affinity resin, which contains plant lectin Galanthus nivalis agglutinin , can bind to alpha 1,3 mannose groups in enveloped viruses. Another study also reported that this device can eliminate SARS-CoV-2 from circulation in vivo.
Among all SARS-CoV-2 variants, the greatest binding affinity was observed against the Brazilian P.1 and Omicron variants. In contrast, the lowest binding affinity was observed against the Delta AY.1 variant, which is more commonly referred to as the Delta Plus strain. An average RNA viral load of severely infected COVID-19 patients contains 103 copies/ml. An adult patient with a blood volume of 5,000 ml would contain 2.5 x 107 viral copies. These numbers suggest that the Hemopurifier has sufficient binding capacity to remove the entire viral load of an adult severely infected with SARS-CoV-2.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cellsChildren typically experience more mild symptoms of COVID-19 when compared to adults; why is this? This study uses nasal epithelial cells from children and adults to show that the ancestral SARS-CoV-2 and Delta, but not the Omicron variant, replicate less efficiently in pediatric nasal epithelial cells.
Read more »
Study suggests peimine may be a potent inhibitor of SARS-CoV-2 variant infectionA recent study published in the Journal of Food Biochemistry discovered that peimine from Fritillaria might be a possible SARS-CoV-2 variant infection inhibitor.
Read more »
Long-term symptoms 23 months after SARS-CoV-2 infectionLong-term symptoms 23 months after SARS-CoV-2 infection symptoms COVID19 coronavirus covid infection SARSCoV2
Read more »
How can researchers profile post-COVID syndromes among distinct SARS-CoV-2 variants?How can researchers profile post-COVID syndromes among distinct SARS-CoV-2 variants? medrxivpreprint KingsCollegeLon SARSCoV2 COVID19 PostCOVIDSyndrome Variant
Read more »
Study indicates that cross-reactive immunity against SARS-CoV-2 N protein was present in Africa prior to the pandemicResearchers assessed the pre-existing cross-protective immune responses against SARS-CoV-2 nucleocapsid protein and spike protein before the COVID-19 pandemic in individuals residing in North and South America, Europe and Africa in vitro and in vivo.
Read more »
The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2The recent progress in investigating the inhibitory impact of nanosponges and antiviral delivery against SARS-CoV-2 StanfordMed nanosponge SARSCoV2 COVID19 coronavirus covid antiviral
Read more »